Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zenas BioPharma
Zenas BioPharma is developing immune-based therapies for autoimmune and rare diseases.
Biotech
Royalty bestows Zenas with $300M for autoimmune approval push
Royalty is paying Zenas $75 million upfront, with similar payments coming if obexelimab succeeds in phase 3 and secures FDA approval.
Darren Incorvaia
Sep 2, 2025 11:07am
J&J innovator vaults to Valo—Chutes & Ladders
Apr 11, 2025 8:30am
Former FDA deputy joins AI biotech's board—Chutes & Ladders
Mar 21, 2025 8:30am
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
Zenas, MBX, Bicara head to Nasdaq in hot day for biotech IPOs
Sep 13, 2024 5:25am
Zenas, Bicara set out to raise $180M-plus in separate IPOs
Sep 6, 2024 8:18am
